Why the study?
Does intravenous acebutolol improve supraventricular arrhythmias in affected patients?
Does intravenous acebutolol improve supraventricular arrhythmias in affected patients?
Intravenous acebutolol is effective for the acute management of various supraventricular arrhythmias and appears well-tolerated even in patients with chronic obstructive pulmonary disease.
May support acute rate control with IV acebutolol in AF/flutter; hypothesis-generating case report leaves open need for randomized confirmation.
The effect of intravenous acebutolol on supraventricular arrhythmias was evaluated in 20 patients, 5 with chronic obstructive pulmonary disease. A rapid ventricular rate in atrial fibrillation was slowed greater than 15% in all of 10 patients by acebutolol and in none of 5 patients by saline. A rapid ventricular rate in atrial flutter was slowed greater than 15% in all of 6 patients by acebutolol and in none of 3 patients by saline. Frequent premature atrial beats were abolished or reduced by greater than 75% in each of 2 patients by acebutolol and not in a patient by saline. Acebutolol converted multifocal atrial tachycardia to sinus rhythm in a patient. Digitalis-induced nonparoxysmal atrioventricular junctional tachycardia was not affected by saline but was abolished by acebutolol in a patient. Acebutolol was well tolerated in each of 5 patients with chronic obstructive pulmonary disease. Acebutolol is useful in the treatment of supraventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
Aronow et al. (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: